We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
DEXMEDETOMIDINE KABI (Fresenius Kabi Australia Pty Ltd)
Product name
DEXMEDETOMIDINE KABI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
161 working days (255)
Active ingredients
dexmedetomidine hydrochloride
Registration type
New generic medicine
Indication
DEXMEDETOMIDINE KABI (concentrated injection vial) is indicated for:
- sedation of initially intubated patients during treatment in an intensive care setting. The use of DEXMEDETMIDINE KABI by continuous infusion in these patients should not exceed 24 hours.
- sedation of non-intubated patients prior to and/or during surgical and other procedures